MPN mouse modelling of the disease will be important to understand the precise role of this increased CXCL12/CXCR4 activity in the development of EMH and whether spleen reduction by JAK2 inhibitor is mainly mediated by induction of mobilization. Here, CXCR4 is linked to myeloproliferative disorder.